Technical Analysis for BBIO - BridgeBio Pharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Gapped Down | Weakness | 0.00% | |
| Inside Day | Range Contraction | -2.90% | |
| Gapped Down | Weakness | -2.90% | |
| Inside Day | Range Contraction | -2.66% | |
| BB Squeeze Ended | Range Expansion | -0.21% | |
| Outside Day | Range Expansion | -0.21% | |
| Down 3 Days in a Row | Weakness | -0.21% | |
| Down 4 Days in a Row | Weakness | -0.21% | |
| Down 5 Days in a Row | Weakness | -0.21% | |
| MACD Bearish Signal Line Cross | Bearish | -1.57% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 12 hours ago |
| Gap Down Closed | about 18 hours ago |
| Reversed from Down | about 18 hours ago |
| Gap Down Partially Closed | about 18 hours ago |
| Gapped Down (Partial) | about 18 hours ago |
Get a Trading Assistant
- Earnings date: 10/31/2024
BridgeBio Pharma, Inc. Description
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Clinical Development Protein Kinase Inhibitor Tyrosine Kinase Tyrosine Kinase Receptors Amyloid Amyloidosis Cardiomyopathy Hyperplasia Myopathy Fibroblast Growth Factor Receptor Transthyretin Achondroplasia Congenital Adrenal Hyperplasia Familial Amyloid Polyneuropathy Polyneuropathy TTR Amyloidosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 44.32 |
| 52 Week Low | 21.62 |
| Average Volume | 2,048,262 |
| 200-Day Moving Average | 28.20 |
| 50-Day Moving Average | 25.97 |
| 20-Day Moving Average | 24.98 |
| 10-Day Moving Average | 24.75 |
| Average True Range | 1.04 |
| RSI (14) | 40.12 |
| ADX | 17.29 |
| +DI | 13.30 |
| -DI | 25.75 |
| Chandelier Exit (Long, 3 ATRs) | 23.67 |
| Chandelier Exit (Short, 3 ATRs) | 25.86 |
| Upper Bollinger Bands | 26.62 |
| Lower Bollinger Band | 23.35 |
| Percent B (%b) | 0.14 |
| BandWidth | 13.09 |
| MACD Line | -0.44 |
| MACD Signal Line | -0.34 |
| MACD Histogram | -0.1006 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 25.14 | ||||
| Resistance 3 (R3) | 25.29 | 24.98 | 24.92 | ||
| Resistance 2 (R2) | 24.98 | 24.64 | 24.91 | 24.84 | |
| Resistance 1 (R1) | 24.39 | 24.42 | 24.23 | 24.24 | 24.76 |
| Pivot Point | 24.08 | 24.08 | 24.00 | 24.01 | 24.08 |
| Support 1 (S1) | 23.49 | 23.74 | 23.33 | 23.34 | 22.82 |
| Support 2 (S2) | 23.18 | 23.52 | 23.11 | 22.74 | |
| Support 3 (S3) | 22.59 | 23.18 | 22.67 | ||
| Support 4 (S4) | 22.44 |
